Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07830199) titled 'A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Condition:
Solid Tumor
Intervention:
Drug: SHR-4595 for Injection
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 2026
Target Sample Size: 208
Countries of Recruitment:
China
To know more, visit https:/...